Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fleischmann

Showing results (101-110 of 160) with videos related to

Pageof 16
Sort By:
The Journal of Rheumatology|February 9, 2006
Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritisJoan M Bathon, Roy M Fleischmann, Désirée Van der Heijde, et al.
RMD Open|August 6, 2016
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritisRoy M Fleischmann, Tom W J Huizinga, Arthur F Kavanaugh, et al.
Annals of the Rheumatic Diseases|February 20, 2014
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trialGerd-Rűdiger Burmester, Alan J Kivitz, Hartmut Kupper, et al.
Clinical and Experimental Rheumatology|April 19, 2016
Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trialJoel M Kremer, Ricardo Blanco, Anne-Marie Halland, et al.
Arthritis and Rheumatism|April 11, 2003
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trialRoy M Fleischmann, Joy Schechtman, Ralph Bennett, et al.
Annals of the Rheumatic Diseases|December 27, 2012
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitorsMark C Genovese, Roy M Fleischmann, Maria Greenwald, et al.
Archives of Internal Medicine|March 29, 2000
Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluationS H Roth, R M Fleischmann, F X Burch, et al.
Annals of the Rheumatic Diseases|September 15, 2022
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III studyEugen Feist, Saeed Fatenejad, Sergey Grishin, et al.
Current Medical Research and Opinion|August 9, 2005
Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trialR M Fleischmann, S B Cohen, L W Moreland, et al.
Arthritis Research & Therapy|November 29, 2015
Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activityJanet Pope, Clifton O Bingham, Roy M Fleischmann, et al.
Pageof 16

Showing results (101-110 of 160) with videos related to

Sort By:
Pageof 16
The Journal of Rheumatology|February 9, 2006
Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritisJoan M Bathon, Roy M Fleischmann, Désirée Van der Heijde, et al.
RMD Open|August 6, 2016
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritisRoy M Fleischmann, Tom W J Huizinga, Arthur F Kavanaugh, et al.
Annals of the Rheumatic Diseases|February 20, 2014
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trialGerd-Rűdiger Burmester, Alan J Kivitz, Hartmut Kupper, et al.
Clinical and Experimental Rheumatology|April 19, 2016
Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trialJoel M Kremer, Ricardo Blanco, Anne-Marie Halland, et al.
Arthritis and Rheumatism|April 11, 2003
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trialRoy M Fleischmann, Joy Schechtman, Ralph Bennett, et al.
Annals of the Rheumatic Diseases|December 27, 2012
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitorsMark C Genovese, Roy M Fleischmann, Maria Greenwald, et al.
Archives of Internal Medicine|March 29, 2000
Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluationS H Roth, R M Fleischmann, F X Burch, et al.
Annals of the Rheumatic Diseases|September 15, 2022
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III studyEugen Feist, Saeed Fatenejad, Sergey Grishin, et al.
Current Medical Research and Opinion|August 9, 2005
Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trialR M Fleischmann, S B Cohen, L W Moreland, et al.
Arthritis Research & Therapy|November 29, 2015
Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activityJanet Pope, Clifton O Bingham, Roy M Fleischmann, et al.
Pageof 16